Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allovir Inc ALVR

Healthcare Biotechnology
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life... see more

Recent & Breaking News (NDAQ:ALVR)

AlloVir Announces Proposed Public Offering of Common Stock

Business Wire June 21, 2023

AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)

Business Wire June 5, 2023

AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer

Business Wire May 16, 2023

AlloVir Reports First Quarter 2023 Financial Results

Business Wire May 4, 2023

AlloVir to Present at the BofA Securities 2023 Health Care Conference

Business Wire May 1, 2023

AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023

Business Wire April 26, 2023

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors

Business Wire February 23, 2023

AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook

Business Wire February 15, 2023

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Business Wire February 15, 2023

AlloVir to Participate in the SVB Securities Global Biopharma Conference

Business Wire February 1, 2023

AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

Business Wire January 9, 2023

AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2023

AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition

Business Wire December 10, 2022

AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference

Business Wire November 15, 2022

Final Data from AlloVir's Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting

Business Wire November 3, 2022

AlloVir Reports Third Quarter 2022 Financial Results

Business Wire November 3, 2022

AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Business Wire August 31, 2022

AlloVir Reports Second Quarter 2022 Financial Results

Business Wire August 4, 2022

AlloVir Announces $126.6 Million Registered Direct Offering

Business Wire July 27, 2022

AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Business Wire June 7, 2022